[1] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014, 109:950-967. [2] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol, 2019, 70:1222-1261. [3] 周光德, 赵景民, 张玲霞, 等. 药物性肝损伤100例临床病理分析. 中华肝脏病杂志, 2007, 15:212-215. [4] Zhu Y, Niu M, Chen J, et al. Hepatobiliary and pancreatic: Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. J Gastroenterol Hepatol, 2016, 31:1476-1482. [5] Liu Y, Wang W, Sun M, et al. Polygonum multiflorum-induced liver injury: clinical characteristics, risk factors, material basis, action mechanism and current challenges. Front Pharmacol, 2019, 10:1467. [6] Li C, Rao T, Chen X, et al. HLA-B*35:01 Allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans. Hepatology, 2019, 70:346-357. [7] Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology, 2020, 72:671-722. [8] Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol, 2018, 113:175-194. [9] European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017,67:370-398. [10] Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology, 2014, 59:661-670. |